Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $192068.0.

  • Abvc Biopharma's Cash & Equivalents rose 3984.45% to $192068.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $192068.0, marking a year-over-year increase of 3984.45%. This contributed to the annual value of $248382.0 for FY2024, which is 31290.33% up from last year.
  • As of Q3 2025, Abvc Biopharma's Cash & Equivalents stood at $192068.0, which was up 3984.45% from $388251.0 recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Cash & Equivalents ranged from a high of $6.6 million in Q4 2021 and a low of $60155.0 during Q4 2023
  • For the 5-year period, Abvc Biopharma's Cash & Equivalents averaged around $1.5 million, with its median value being $924841.0 (2021).
  • Per our database at Business Quant, Abvc Biopharma's Cash & Equivalents surged by 263800.45% in 2021 and then plummeted by 9567.77% in 2023.
  • Over the past 5 years, Abvc Biopharma's Cash & Equivalents (Quarter) stood at $6.6 million in 2021, then tumbled by 78.8% to $1.4 million in 2022, then crashed by 95.68% to $60155.0 in 2023, then surged by 312.9% to $248382.0 in 2024, then decreased by 22.67% to $192068.0 in 2025.
  • Its Cash & Equivalents was $192068.0 in Q3 2025, compared to $388251.0 in Q2 2025 and $152206.0 in Q1 2025.